American Journal of Clinical Dermatology

, Volume 4, Issue 2, pp 81–95 | Cite as


Etiology, Diagnosis, and Management
  • John J. DiGiovannaEmail author
  • Leslie Robinson-Bostom
Review Article


The ichthyoses are a heterogeneous group of disorders with both inherited and acquired forms. Clinical presentation, pattern of inheritance, and laboratory evaluation may establish a precise diagnosis, which can assist in prognosis and genetic counseling.

Congenital autosomal recessive ichthyosis (CARI) usually presents at birth, often as a collodion baby. CARI can progress into any one of a spectrum of disorders. Lamellar ichthyosis is characterized by dark, plate (armor)-like scale. This disease is often caused by mutations in the gene encoding the enzyme transglutaminase 1. Congenital ichthyosiform erythroderma is another phenotype within CARI, marked by generalized redness and fine white scale.

Epidermolytic hyperkeratosis is an autosomal dominant disorder characterized by hyperkeratosis and blistering, and at least six clinical phenotypes have been described. It may be due to mutations in the gene encoding the intermediate filament proteins keratin 1 and 10.

Ichthyosis vulgaris is the most common ichthyosis, and is inherited in an autosomal dominant pattern. Involvement is generally mild and may vary greatly with climate and humidity. X-linked ichthyosis, due to a defect in the enzyme steroid sulfatase, affects males with generalized scaling that usually begins soon after birth. There may be associated corneal opacities that do not affect vision.

Sjögren-Larsson syndrome is an autosomal recessive ichthyosis associated with progressive spastic paralysis and mental retardation. This condition is caused by mutations in the gene for fatty aldehyde dehydrogenase. Refsum’s disease, due to accumulation of phytanic acid, results in ichthyosis and progressive neurologic dysfunction.

The erythrokeratodermas are characterized by hyperkeratosis and localized erythema. Erythrokeratodermia variabilis is autosomal dominant and characterized by generalized or localized hyperkeratosis and migratory red patches. Mutations in the genes encoding the gap junction proteins, connexins, underlie this disorder.

Netherton’s syndrome is an autosomal recessive disorder characterized by ichthyosis, a hair shaft abnormality and atopy. The ichthyosis may present at birth with erythroderma or in some cases a collodion presentation. However, a frequent characteristic skin manifestation is ichthyosis linearis circumflexa. Netherton’s syndrome has been found to be due to an abnormality in a serum protease inhibitor. Acquired ichthyosis can have a variety of underlying causes including neoplastic, infectious, drugs, endocrine, metabolic, autoimmune, malabsorptive states, and hereditary. Topical, and in more severe cases, systemic, therapy are useful in managing this array of disorders of cornification.


Phytanic Acid Liarozole Calcipotriol Ointment TGM1 Lamellar Ichthyosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr DiGiovanna has received travel and speaking honoraria and clinical research support from Hoffman-LaRoche, and clinical research support from Allergan, who market retinoid drugs.


  1. 1.
    Williams ML, Elias PM. Genetically transmitted, generalized disorders of cornification: the ichthyoses. Dermatol Clin 1987; 5 (1): 155–178PubMedCrossRefGoogle Scholar
  2. 2.
    Williams ML, Elias PM. From basket weave to barrier: unifying concepts for the pathogenesis of the disorders of cornification [editorial]. Arch Dermatol 1993; 129 (5): 626–629PubMedCrossRefGoogle Scholar
  3. 3.
    DiGiovanna JJ. Ichthyosiform dermatoses. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors. Fitzpatrick’s dermatology in general medicine. New York: McGraw-Hill, 1999: 581–603Google Scholar
  4. 4.
    Williams ML, Elias PM. Heterogeneity in autosomal recessive ichthyosis: clinical and biochemical differentiation of lamellar ichthyosis and nonbullous congenital ichthyosiform erythroderma. Arch Dermatol 1985; 121 (4): 477–488PubMedCrossRefGoogle Scholar
  5. 5.
    Hazell M, Marks R. Clinical, histologic, and cell kinetic discriminants between lamellar ichthyosis and nonbullous congenital ichthyosiform erythroderma. Arch Dermatol 1985; 121 (4): 489–493PubMedCrossRefGoogle Scholar
  6. 6.
    Laiho E, Ignatius J, Mikkola H, et al. Transglutaminase 1 mutations in autosomal recessive congenital ichthyosis: private and recurrent mutations in an isolated population. Am J Hum Genet 1997; 61 (3): 529–538PubMedCrossRefGoogle Scholar
  7. 7.
    Bale SJ, Russell LJ, Lee ML, et al. Congenital recessive ichthyosis unlinked to loci for epidermal transglutaminases. J Invest Dermatol 1996; 107 (6): 808–811PubMedCrossRefGoogle Scholar
  8. 8.
    Fischer J, Faure A, Bouadjar B, et al. Two new loci for autosomal recessive ichthyosis on chromosomes 3p21 and 19p12-q12 and evidence for further genetic heterogeneity. Am J Hum Genet 2000 Mar; 66 (3): 904–913PubMedCrossRefGoogle Scholar
  9. 9.
    Virolainen E, Wessman M, Hovatta I, et al. Assignment of a novel locus for autosomal recessive congenital ichthyosis to chromosome 19p13.1-p13.2. Am J Hum Genet 2000; 66 (3): 1132–1137PubMedCrossRefGoogle Scholar
  10. 10.
    Frenk E, de Techtermann F. Self-healing collodion baby: evidence for autosomal recessive inheritance. Pediatr Dermatol 1992; 9 (2): 95–97PubMedCrossRefGoogle Scholar
  11. 11.
    DiGiovanna JJ, Bale SJ. Clinical heterogeneity in epidermolytic hyperkeratosis. Arch Dermatol 1994; 130 (8): 1026–1035PubMedCrossRefGoogle Scholar
  12. 12.
    DiGiovanna JJ, Bale SJ. Epidermolytic hyperkeratosis: applied molecular genetics. J Invest Dermatol 1994; 102 (3): 390–394PubMedCrossRefGoogle Scholar
  13. 13.
    Rothnagel JA, Traupe H, Wojcik S, et al. Mutations in the rod domain of keratin 2e in patients with ichthyosis bullosa of Siemens. Nat Genet 1994; 7 (4): 485–490PubMedCrossRefGoogle Scholar
  14. 14.
    Wells RS, Kerr CB. Clinical features of autosomal dominant and sex-linked ichthyosis in an English population. BMJ 1966; 1: 947–950PubMedCrossRefGoogle Scholar
  15. 15.
    Anton-Lamprecht I, Hofbauer M. Ultrastructural distinctive features of autosomal dominant ichthyosis vulgaris and X-linked recessive ichthyosis. Dermatologica 1972; 145 (1): 60–64PubMedCrossRefGoogle Scholar
  16. 16.
    Sybert VP, Dale BA, Holbrook KA. Ichthyosis vulgaris: identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. J Invest Dermatol 1985; 84 (3): 191–194PubMedCrossRefGoogle Scholar
  17. 17.
    Nirunsuksiri W, Presland RB, Brumbaugh SG, et al. Decreased profilaggrin expression in ichthyosis vulgaris is a result of selectively impaired posttranscriptional control. J Biol Chem 1995; 270 (2): 871–876PubMedCrossRefGoogle Scholar
  18. 18.
    Richard G, Lin JP, Smith L, et al. Linkage studies in erythrokeratodermias: fine mapping, genetic heterogeneity and analysis of candidate genes. J Invest Dermatol 1997; 109 (5): 666–671PubMedCrossRefGoogle Scholar
  19. 19.
    Richard G, Smith LE, Bailey RA, et al. Mutations in the human connexin gene GJB3 cause erythrokeratodermia variabilis. Nat Genet 1998; 20 (4): 366–369PubMedCrossRefGoogle Scholar
  20. 20.
    Rizzo WB, Craft DA. Sjogren-Larsson syndrome, deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol: NAD+ oxidoreductase in cultured fibroblasts. J Clin Invest 1991; 88 (5): 1643–1648PubMedCrossRefGoogle Scholar
  21. 21.
    Rizzo WB, Carney G, Lin Z. The molecular basis of Sjogren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am J Hum Genet 1999; 65 (6): 1547–1560PubMedCrossRefGoogle Scholar
  22. 22.
    De Laurenzi V, Rogers GR, Hamrock DJ, et al. Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 1996; 12 (1): 52–57PubMedCrossRefGoogle Scholar
  23. 23.
    Rizzo WB, Craft DA, Kelson TL, et al. Prenatal diagnosis of Sjogren-Larsson syndrome using enzymatic methods. Prenat Diagn 1994; 14 (7): 577–581PubMedCrossRefGoogle Scholar
  24. 24.
    Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000 Jun; 25 (2): 141–142PubMedCrossRefGoogle Scholar
  25. 25.
    Hochner I, Blickle JF, Brogard JM. Refsum disease. Rev Med Interne 1996; 17 (5): 391–398PubMedCrossRefGoogle Scholar
  26. 26.
    Kitareewan S, Burka LT, Tomer KB, et al. Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol Biol Cell 1996; 7 (8): 1153–1166PubMedGoogle Scholar
  27. 27.
    Itin PH, Sarasin A, Pittelkow MR. Trichothiodystrophy: update on the sulfur-deficient brittle hair syndromes. J Am Acad Dermatol 2001; 44 (6): 891–920PubMedCrossRefGoogle Scholar
  28. 28.
    Takayama K, Salazar EP, Broughton BC, et al. Defects in the DNA repair and transcription gene ERCC2 (XPD) in trichothiodystrophy. Am J Hum Genet 1996; 58 (2): 263–270PubMedGoogle Scholar
  29. 29.
    Weeda G, Eveno E, Donker I, et al. A mutation in the XPB/ERCC3 DNA repair transcription gene, associated with trichothiodystrophy. Am J Hum Genet 1997; 60 (2): 320–329PubMedGoogle Scholar
  30. 30.
    Stefanini M, Vermeulen W, Weeda G, et al. A new nucleotide-excision-repair gene associated with the disorder trichothiodystrophy. Am J Hum Genet 1993; 53 (4): 817–821PubMedGoogle Scholar
  31. 31.
    Griffiths WAD, Judge MR, Leigh IM. Disorders of keratinization. In: Champion RH, Burton JL, Burns DA, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. Oxford: Blackwell Science, 1998: 1483–1530Google Scholar
  32. 32.
    Sneddon IB. Acquired ichthyosis in Hodgkin’s disease. Br J Dermatol 1955; 1: 763–764Google Scholar
  33. 33.
    Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin’ disease. Br J Dermatol 1995; 133 (2): 322–325PubMedCrossRefGoogle Scholar
  34. 34.
    Cheesbrough MJ. Acquired ichthyosis and unclassified lymphoma. Br J Dermatol 1978; 99 Suppl. 16: 26–27PubMedCrossRefGoogle Scholar
  35. 35.
    Tamura J, Shinohara M, Matsushima T, et al. Acquired ichthyosis as a manifestation of abdominal recurrence of non-Hodgkin’s lymphoma [letter]. Am J Hematol 1994; 45 (2): 191–192PubMedCrossRefGoogle Scholar
  36. 36.
    Kutting B, Metze D, Luger TA, et al. Mycosis fungoides presenting as an acquired ichthyosis. J Am Acad Dermatol 1996; 34 (5 Pt 2): 887–889PubMedCrossRefGoogle Scholar
  37. 37.
    Ikada J, Oki M. Concurrent pityriasis rotunda and acquired ichthyosis with IgG myeloma. Br J Dermatol 1974; 91 (5): 585–586PubMedCrossRefGoogle Scholar
  38. 38.
    Haste AR. Acquired ichthyosis from breast cancer. BMJ 1967; 4 (571): 96PubMedCrossRefGoogle Scholar
  39. 39.
    Polisky RB, Bronson DM. Acquired ichthyosis in a patient with adenocarcinoma of the breast. Cutis 1986; 38 (6): 359–360PubMedGoogle Scholar
  40. 40.
    Flint GL, Flam M, Soter NA. Acquired ichthyosis: a sign of nonlymphoproliferative malignant disorders. Arch Dermatol 1975; 111 (11): 1446–1447PubMedCrossRefGoogle Scholar
  41. 41.
    Krakowski A, Brenner S, Covo J, et al. Acquired ichthyosis in Kaposi’s sarcoma. Dermatologica 1973; 147 (5): 348–351PubMedCrossRefGoogle Scholar
  42. 42.
    Bechtel MA, Callen JP. Disseminated Kaposi’s sarcoma in a patient with acquired ichthyosis. J Surg Oncol 1984; 26 (1): 22–26PubMedCrossRefGoogle Scholar
  43. 43.
    Young L, Steinman HK. Acquired ichthyosis in a patient with acquired immunodeficiency syndrome and Kaposi’s sarcoma [letter]. J Am Acad Dermatol 1987; 16 (2 Pt 1): 395–396CrossRefGoogle Scholar
  44. 44.
    Grattan CE, Williams DM, Raafat F, et al. Acquired ichthyosis in a child with rhabdomyosarcoma. Pediatr Dermatol 1988; 5 (3): 167–169PubMedCrossRefGoogle Scholar
  45. 45.
    Farrell AM, Ross JS, Thomas JM, et al. Acquired ichthyosis, alopecia and loss of hair pigment associated with leiomyosarcoma. J Eur Acad Dermatol Venereol 1998; 10 (2): 159–163PubMedCrossRefGoogle Scholar
  46. 46.
    Majekodunmi AE, Femi-Pearse D. Ichthyosis: early manifestation of intestinal leiomyosarcoma. BMJ 1974; 3 (5933): 724PubMedCrossRefGoogle Scholar
  47. 47.
    Bergman R, Friedman-Birnbaum R, Carter A. Acquired ichthyosis in a patient with polycythemia rubra vera. Cutis 1985; 36 (2): 157–158PubMedGoogle Scholar
  48. 48.
    Kato N, Yasukawa K, Kimura K, et al. Anaplastic large-cell lymphoma associated with acquired ichthyosis. J Am Acad Dermatol 2000 May; 42 (5 Pt 2): 914–920CrossRefGoogle Scholar
  49. 49.
    Yokote R, Iwatsuki K, Hashizume H, et al. Lymphomatoid papulosis associated with acquired ichthyosis. J Am Acad Dermatol 1994; 30 (5 Pt 2): 889–892CrossRefGoogle Scholar
  50. 50.
    Schulz EJ. Ichthyosiform conditions occurring in leprosy. Br J Dermatol 1965; 77: 151–157PubMedCrossRefGoogle Scholar
  51. 51.
    Goodman DS, Teplitz ED, Wishner A, et al. Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. J Am Acad Dermatol 1987; 17 (2 Pt 1): 210–220CrossRefGoogle Scholar
  52. 52.
    Coldiron BM, Bergstresser PR. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 1989; 125 (3): 357–361PubMedCrossRefGoogle Scholar
  53. 53.
    Singh M, Kaur S, Kumar B, et al. The associated diseases with leprosy. Indian J Lepr 1987; 59 (3): 315–321PubMedGoogle Scholar
  54. 54.
    Kaplan MH, Sadick NS, McNutt NS, et al. Acquired ichthyosis in concomitant HIV-1 and HTLV-II infection: a new association with intravenous drug abuse. J Am Acad Dermatol 1993; 29 (5 Pt 1): 701–708CrossRefGoogle Scholar
  55. 55.
    Griffiths CE, Leonard JN, Walker MM. Acquired ichthyosis and sarcoidosis. Clin Exp Dermatol 1986; 11 (3): 296–298PubMedCrossRefGoogle Scholar
  56. 56.
    Banse-Kupin L, Pelachyk JM. Ichthyosiform sarcoidosis: report of two cases and a review of the literature. J Am Acad Dermatol 1987; 17 (4): 616–620PubMedCrossRefGoogle Scholar
  57. 57.
    Cather JC, Cohen PR. Ichthyosiform sarcoidosis. J Am Acad Dermatol 1999; 40 (5 Pt 2): 862–865PubMedGoogle Scholar
  58. 58.
    London RD, Lebwohl M. Acquired ichthyosis and hyperparathyroidism. J Am Acad Dermatol 1989; 21 (4 Pt 1): 801–802CrossRefGoogle Scholar
  59. 59.
    Font J, Bosch X, Ingelmo M, et al. Acquired ichthyosis in a patient with systemic lupus erythematosus [letter]. Arch Dermatol 1990; 126 (6): 829PubMedCrossRefGoogle Scholar
  60. 60.
    Duvic M, Jegasothy BV. Acquired ichthyosis with systemic lupus erythematosus. Arch Dermatol 1980; 116 (8): 952–954PubMedCrossRefGoogle Scholar
  61. 61.
    Urrutia S, Vazquez F, Requena L, et al. Acquired ichthyosis associated with dermatomyositis [letter]. J Am Acad Dermatol 1987; 16 (3 Pt 1): 627–629CrossRefGoogle Scholar
  62. 62.
    Roselino AM, Souza CS, Andrade JM, et al. Dermatomyositis and acquired ichthyosis as paraneoplastic manifestations of ovarian tumor. Int J Dermatol 1997; 36 (8): 611–614PubMedCrossRefGoogle Scholar
  63. 63.
    de la Cruz-Alvarez J, Allegue F, Oliver J. Acquired ichthyosis associated with eosinophilic fasciitis. J Am Acad Dermatol 1996; 34 (6): 1079–1080PubMedCrossRefGoogle Scholar
  64. 64.
    Spelman LJ, Strutton GM, Robertson IM, et al. Acquired ichthyosis in bone marrow transplant recipients. J Am Acad Dermatol 1996; 35 (1): 17–20PubMedCrossRefGoogle Scholar
  65. 65.
    Dilek I, Demirer T, Ustun C, et al. Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia. Bone Marrow Transplant 1998; 21 (11): 1159–1161PubMedCrossRefGoogle Scholar
  66. 66.
    Parsons Jr WB. Treatment of hypercholesteremia by nicotinic acid: progress report with review of studies regarding mechanism of action. Arch Intern Med (Chicago) 1961; 107: 639–652Google Scholar
  67. 67.
    Winkelmann RK, Perry HO, Achor RW, et al. Cutaneous syndromes produced as side effects of triparanol therapy. Arch Derm (Chicago) 1963; 87: 372–377CrossRefGoogle Scholar
  68. 68.
    Greist MC, Epinette WW. Cimetidine-induced xerosis and asteatotic dermatitis. Arch Dermatol 1982; 118 (4): 253–254PubMedCrossRefGoogle Scholar
  69. 69.
    Caver CV. Clofazimine-induced ichthyosis and its treatment. Cutis 1982; 29 (4): 341–343PubMedGoogle Scholar
  70. 70.
    Williams ML, Feingold KR, Grubauer G, et al. Ichthyosis induced by cholesterollowering drugs: implications for epidermal cholesterol homeostasis. Arch Dermatol 1987; 123 (11): 1535–1538PubMedCrossRefGoogle Scholar
  71. 71.
    Niederauer HH, Bacharach-Buhles M, Altmeyer P. Ichthyosis and alopecia after maprotiline: corneolysis caused by temporary disorder of keratinization [in German]. Hautarzt 1991; 42 (7): 455–458PubMedGoogle Scholar
  72. 72.
    Epstein Jr EH, Bonifas JM. Recessive X-linked ichthyosis: lack of immunologically detectable steroid sulfatase enzyme protein. Hum Genet 1985; 71 (3): 201–205PubMedCrossRefGoogle Scholar
  73. 73.
    Epstein Jr EH, Krauss RM, Shackleton CH. X-linked ichthyosis: increased blood cholesterol sulfate and electrophoretic mobility of low-density lipoprotein. Science 1981; 214 (4521): 659–660PubMedCrossRefGoogle Scholar
  74. 74.
    Chipev CC, Yang JM, DiGiovanna JJ, et al. Preferential sites in keratin 10 that are mutated in epidermolytic hyperkeratosis. Am J Hum Genet 1994; 54 (2): 179–190PubMedGoogle Scholar
  75. 75.
    Bale SJ, DiGiovanna JJ. Genetic approaches to understanding the keratinopathies. Adv Dermatol 1997; 12: 99–114PubMedGoogle Scholar
  76. 76.
    GeneTests GeneClinics. Laboratory directory [online]. Available from URL: [Accessed 2002 Dec 6]Google Scholar
  77. 77.
    Frost P, Van Scott EJ. Ichthyosiform dermatoses: classification based on anatomic and biometric observations. Arch Dermatol 1966; 94 (2): 113–126PubMedCrossRefGoogle Scholar
  78. 78.
    Ishida-Yamamoto A, McGrath JA, Judge MR, et al. Selective involvement of keratins K1 and K10 in the cytoskeletal abnormality of epidermolytic hyperkeratosis (bullous congenital ichthyosiform erythroderma). J Invest Dermatol 1992; 99 (1): 19–26PubMedCrossRefGoogle Scholar
  79. 79.
    Robinson-Bostom L, McDonald CJ. Ichthyosis. In: McDonald CJ, editor. Immunomodulatory and cytotoxic agents in dermatology. New York: Marcel Deckker, 1997: 293–300Google Scholar
  80. 80.
    Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137 (6): 747–750PubMedGoogle Scholar
  81. 81.
    Gibberd FB, Billimoria JD, Page NG, et al. Heredopathia atactica polyneuritiformis (Refsum’s disease) treated by diet and plasma-exchange. Lancet 1979; I (8116): 575–578CrossRefGoogle Scholar
  82. 82.
    Moser HW, Braine H, Pyeritz RE, et al. Therapeutic trial of plasmapheresis in Refsum disease and in Fabry disease. Birth Defects Orig Artic Ser 1980; 16 (1): 491–497PubMedGoogle Scholar
  83. 83.
    Goldsmith LA, Baden HP. Propylene glycol with occlusion for treatment of ichthyosis. JAMA 1972; 220 (4): 579–580PubMedCrossRefGoogle Scholar
  84. 84.
    Germann R, Schindera I, Kuch M, et al. Life threatening salicylate poisoning caused by percutaneous absorption in severe ichthyosis vulgaris [in German]. Hautarzt 1996; 47 (8): 624–627PubMedCrossRefGoogle Scholar
  85. 85.
    Chiaretti A, Schembri Wismayer D, Tortorolo L, et al. Salicylate intoxication using a skin ointment. Acta Paediatr 1997; 86 (3): 330–331PubMedCrossRefGoogle Scholar
  86. 86.
    Redondo P, Bauza A. Topical N-acetylcysteine for lamellar ichthyosis [letter]. Lancet 1999; 354 (9193): 1880PubMedCrossRefGoogle Scholar
  87. 87.
    Kragballe K, Steijlen PM, Ibsen HH, et al. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization: results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995; 131 (5): 556–560PubMedCrossRefGoogle Scholar
  88. 88.
    Lucker GP, van de Kerkhof PC, van Dijk MR, et al. Effect of topical calcipotriol on congenital ichthyoses. Br J Dermatol 1994; 131 (4): 546–550PubMedCrossRefGoogle Scholar
  89. 89.
    Lucker GP, van de Kerkhof PC, Cruysberg JR, et al. Topical treatment of Sjogren-Larsson syndrome with calcipotriol. Dermatology 1995; 190 (4): 292–294PubMedCrossRefGoogle Scholar
  90. 90.
    Steijlen PM, Reifenschweiler DO, Ramaekers FC, et al. Topical treatment of ichthyoses and Darier’s disease with 13-cis- retinoic acid: a clinical and immunohistochemical study. Arch Dermatol Res 1993; 285 (4): 221–226PubMedCrossRefGoogle Scholar
  91. 91.
    Hofmann B, Stege H, Ruzicka T, et al. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999; 141 (4): 642–646PubMedCrossRefGoogle Scholar
  92. 92.
    Jensen TG, Jensen UB, Jensen PK, et al. Correction of steroid sulfatase deficiency by gene transfer into basal cells of tissue-cultured epidermis from patients with recessive X-linked ichthyosis. Exp Cell Res 1993; 209 (2): 392–397PubMedCrossRefGoogle Scholar
  93. 93.
    Choate KA, Medalie DA, Morgan JR, et al. Corrective gene transfer in the human skin disorder lamellar ichthyosis. Nat Med 1996; 2 (11): 1263–1267PubMedCrossRefGoogle Scholar
  94. 94.
    Peck GL, DiGiovanna JJ. The retinoids. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors. Fitzpatrick’s dermatology in general medicine. New York: McGraw-Hill, 1999: 2810–2820Google Scholar
  95. 95.
    DiGiovanna JJ, Peck GL. Oral synthetic retinoid treatment in children. Pediatr Dermatol 1983; 1 (1): 77–88PubMedCrossRefGoogle Scholar
  96. 96.
    Virtanen M, Gedde-Dahl Jr T, Mork NJ, et al. Phenotypic/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression. Acta Derm Venereol 2001; 81 (3): 163–170PubMedCrossRefGoogle Scholar
  97. 97.
    Soriatane package insert. Nutley (NJ): Roche Laboratories Inc., 2001 JanGoogle Scholar
  98. 98.
    Isotretinoin package insert. Nutley (NJ): Roche Laboratories Inc., 2002 JunGoogle Scholar
  99. 99.
    DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45 (5): S176–S182PubMedCrossRefGoogle Scholar
  100. 100.
    Lucker GP, Heremans AM, Boegheim PJ, et al. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 1997; 136 (1): 71–75PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • John J. DiGiovanna
    • 1
    • 2
    • 3
    Email author
  • Leslie Robinson-Bostom
    • 2
    • 4
  1. 1.Division of DermatopharmacologyBrown Medical School and Rhode Island HospitalProvidenceUSA
  2. 2.Department of DermatologyBrown Medical School and Rhode Island HospitalProvidenceUSA
  3. 3.Basic Research LaboratoryCenter for Cancer Research, National Cancer Institute, National Institutes of HealthBethesdaUSA
  4. 4.Department of PathologyRhode Island HospitalProvidenceUSA

Personalised recommendations